Roxadustat meets in Phase III for CKD patients with anemia not on dialysis

Astellas Pharma Inc. (Tokyo:4503) said roxadustat (ASP1517, FG-4592) met both primary endpoints in the Phase III ALPS trial to treat anemia in patients with chronic kidney disease (CKD) who were not receiving dialysis.

On the primary endpoint for a

Read the full 387 word article

User Sign In